Neuroblastoma in adolescents: genetic and clinical characterisation

被引:26
作者
Castel, Victoria [1 ]
Villamon, Eva [2 ]
Canete, Adela [1 ]
Navarro, Samuel [2 ]
Ruiz, Amparo [2 ]
Melero, Carmen [3 ]
Herrero, Antonio [4 ]
Yanez, Yania [1 ]
Noguera, Rosa [2 ]
机构
[1] Hosp Univ La Fe, Unidad Oncol Pediat, ES-46009 Valencia, Spain
[2] Univ Valencia, Fac Med, Dept Patol, Valencia, Spain
[3] Hosp 12 Octubre, Unidad Oncol Pediat, E-28041 Madrid, Spain
[4] Hosp Carlos Haya, Unidad Oncol Pediat, Malaga, Spain
关键词
Neuroblastoma; Adolescents; MYCN; 11q; 17q; MLPA; COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RISK NEUROBLASTOMA; INDOLENT COURSE; ADULTS; 11Q; STRATIFICATION; EXPERIENCE; DIAGNOSIS; CHILDREN; SURVIVAL;
D O I
10.1007/s12094-010-0466-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Age at diagnosis is an important risk factor in neuroblastoma (NB) with worse prognosis in children older than 18 months. A more indolent course with long-term relapses and fatal outcome has been described in small series of adolescents. Our objective was to describe biological factors that contribute to this particular behaviour and could be helpful in their treatment. Procedure NB cases older than 10 years of age at diagnosis registered in the files of the Neuroblastoma Group of SEOP from 1992 to 2007 were included. Disease extension was classified according to the International Neuroblastoma Staging System (INSS). Tumour samples were studied according to the International Neuroblastoma Pathology Classification (INPC). Biological studies included MNA, 1p, 11q and 17q status and ploidy. Results Twenty-two patients, from 10.1 to 24.6 years old, were included. Advanced stages predominated. 14/17 patients presented unfavourable histology. None had NMA or 1p del. However, 11q del was found in 8/13 cases and 17q gain in 7/11. Overall survival ( OS) and event-free survival (EFS) for the entire series at 5 years were 0.45 and 0.32, respectively. Moreover, 5-year OS and EFS for stage 4 patients were 0.33 and 0.15. Conclusions NB in adolescents is a special subgroup characterised by high-risk prognostic features which differ from those seen in younger patients, especially in relation to genetic abnormalities. The outcome in stage 4 was worse than in younger metastatic children, outlining the need for new therapeutic approaches in this subgroup of patients. The exact cut-off to separate older patients has not yet been established and will probably be based on biology.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 31 条
  • [1] Quality assessment of genetic markers used for therapy stratification
    Ambros, IM
    Benard, J
    Boavida, M
    Bown, N
    Caron, H
    Combaret, V
    Couturier, J
    Darnfors, C
    Delattre, O
    Freeman-Edward, J
    Gambini, C
    Gross, N
    Hattinger, CM
    Luegmayr, A
    Lunec, J
    Martinsson, T
    Mazzocco, K
    Navarro, S
    Noguera, R
    O'Neill, S
    Pötschger, U
    Rumpler, S
    Speleman, F
    Tonini, GP
    Valent, A
    Van Roy, N
    Amann, G
    De Bernardi, B
    Kogner, P
    Ladenstein, R
    Mickon, J
    Pearson, ADJ
    Ambros, PF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2077 - 2084
  • [2] Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Attiyeh, EF
    London, WB
    Mossé, YP
    Wang, Q
    Winter, C
    Khazi, D
    McGrady, PW
    Seeger, RC
    Look, AT
    Shimada, H
    Brodeur, GM
    Cohn, SL
    Matthay, KK
    Maris, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2243 - 2253
  • [3] BLATT J, 1995, CANCER, V76, P890, DOI 10.1002/1097-0142(19950901)76:5<890::AID-CNCR2820760525>3.0.CO
  • [4] 2-X
  • [5] Bown N, 2001, MED PEDIATR ONCOL, V36, P14, DOI 10.1002/1096-911X(20010101)36:1<14::AID-MPO1005>3.0.CO
  • [6] 2-G
  • [7] Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization
    Breen, CJ
    O'Meara, A
    McDermott, M
    Mullarkey, M
    Stallings, RL
    [J]. CANCER GENETICS AND CYTOGENETICS, 2000, 120 (01) : 44 - 49
  • [8] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477
  • [9] Brodeur GM., 2002, Principles and practice of pediatric Oncology, P895
  • [10] Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors:: a study of 182 cases from the Spanish Neuroblastoma Registry
    Burgues, Octavio
    Navarro, Samuel
    Noguera, Rosa
    Pellin, Antonio
    Ruiz, Amparo
    Castel, Victoria
    Llombart-Bosch, Antonio
    [J]. VIRCHOWS ARCHIV, 2006, 449 (04) : 410 - 420